BioCryst Pharmaceuticals, Inc. (BCRX)
8.325
-0.10
(-1.25%)
USD |
NASDAQ |
Jun 09, 16:00
8.325
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Research and Development Expense (Quarterly) : 59.26M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Dyne Therapeutics, Inc. | 100.89M |
| Taysha Gene Therapies, Inc. | 33.51M |
| Agenus, Inc. | 11.82M |
| Amgen, Inc. | 1.719B |
| Imunon, Inc. | 2.337M |